Tag: CBT > FDA Policy on CBD: Page 3

Hemp Research

What’s Up With Pet CBD?

As consumer interest in cannabinoids for pets increases, so do questions about capitalizing on the growing market.

May 11, 2022

Compliance

Selling Hemp-Derived Delta-9 THC Products? Here's What to Consider

Marshall Custer of Husch Blackwell law firm dives into legal considerations for hemp businesses selling these products.

May 10, 2022

Interviews & Opinion

FDA Issues First Batch of Warning Letters to Delta-8 THC Product Manufacturers

The federal agency is warning five companies that they are marketing unapproved new drugs, misbranding their wares and unlawfully adding delta-8 THC to food products.

May 6, 2022

Legislation and Regulation

FDA Issues Warning Letters to Companies Claiming Their CBD Products Can Treat COVID-19

The federal agency is warning seven companies that they are falsely advertising their wares.

April 1, 2022

Interviews & Opinion

Cannabis in the New Year: 5 Key Trends to Watch

Jonathan Havens and Marc Adesso, leaders in Saul Ewing Arnstein & Lehr’s Cannabis Law Practice, share the developments from 2021 that will impact the industry’s outlook in 2022.

December 17, 2021

International

Global Companies Expand Work on Cannabis-Based Epilepsy Treatments

Representatives of companies with global footprints discuss the goals behind the research, governmental approval and sale of cannabis compounds for epileptic conditions.

December 3, 2021

Interviews & Opinion

FDA’s Rejection of CBD New Dietary Ingredient Notifications: Four Practical Takeaways

Kelley Drye & Warren’s Kristi Wolff breaks down the most important aspects of the government agency’s decision on the hemp-derived cannabinoid.

September 17, 2021

Legislation and Regulation

FDA Balks at CBD Dietary Supplement Application, Maintaining Regulatory Uncertainty

Citing its own approval of CBD as an active ingredient in Epidiolex, the FDA sees the cannabinoid as pharmaceutical constituent.

August 12, 2021

CBD Industry

CBD Sales Both Boosted, Thwarted by COVID-19

Price compression and the economic downturn continue to be challenges, though sales volume has increased.

September 28, 2020

Legislation and Regulation

9 Amicus Briefs Filed with Supreme Court in Support of Removing Cannabis from Controlled Substances Act

Eight industry organizations and seven members of Congress all wrote in support of Marvin Washington’s appeal to the country’s highest court.

September 17, 2020

CBD Industry

FDA Submits ‘Cannabidiol Enforcement Policy’ Draft to White House

While the contents of the document are still unknown, the FDA described it as “draft guidance for the industry.”

July 24, 2020

CBD Industry

FDA Warns Two Companies to Stop Marketing CBD as Opioid Addiction Treatment

The letters were sent to BIOTA Biosciences LLC and Homero Corp, the latter of which conducts business as Natures CBD Oil Distribution.

April 30, 2020